Eli Lilly is a pharmaceutical leader behind blockbuster GLP-1 drugs for diabetes and obesity (Mounjaro, Zepbound). It trades on NYSE under the ticker LLY, in the Pharmaceuticals sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | LLY |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Headquarters | Indianapolis, IN, USA |
Bull Case & Risks
Bull Case
- Dominant GLP-1 obesity and diabetes franchise
- A deep late-stage pipeline
- A huge, still-expanding obesity market
Risks
- High valuation built on growth expectations
- Drug-pricing pressure and rising competition
Outlook
Eli Lilly is the leading obesity-drug franchise with a vast addressable market; the bull case is durable GLP-1 demand, the risk is the premium it commands.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.